Degarelix Neo-Adjuvant Radical Prostatectomy Trial
NCT01674270 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2015-12-22
Summary
To assess the effect of neo-adjuvant GnRH antagonist, degarelix, versus LHRH agonist on intratumoral levels of androgens.
Conditions
Interventions
- DRUG
-
Degarelix
- DRUG
-
Casodex
- DRUG
-
LHRH Agonist
Sponsors & Collaborators
-
University Health Network, Toronto
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-08-31
- Primary Completion
- 2014-12-31
- Completion
- 2015-11-30
Countries
- Canada
Study Locations
More Related Trials
-
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
NCT01630967 ·Status: UNKNOWN ·Phase: PHASE2
-
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
NCT00295750 ·Status: COMPLETED ·Phase: PHASE3
-
Degarelix Before Radical Prostatectomy
NCT01852864 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
NCT00738673 ·Status: COMPLETED ·Phase: PHASE2
-
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
NCT02799706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
NCT00116753 ·Status: COMPLETED ·Phase: PHASE2
-
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
NCT00245466 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
NCT03080116 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
NCT00967018 ·Status: COMPLETED ·Phase: PHASE3
-
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
NCT02234089 ·Status: COMPLETED
-
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
NCT01344564 ·Status: COMPLETED ·Phase: NA
-
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
NCT00819247 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label, Randomised Parallel-Group Study
NCT00728533 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
NCT02526784 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Degarelix in Patients With Prostate Cancer
NCT00946920 ·Status: COMPLETED ·Phase: PHASE3
-
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
NCT00468286 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiovascular Events in GnRH Agonist vs. Antagonist
NCT04182594 ·Status: UNKNOWN ·Phase: PHASE2
-
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
NCT01491971 ·Status: COMPLETED ·Phase: PHASE2
-
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
NCT01366053 ·Status: COMPLETED
-
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
NCT00801242 ·Status: COMPLETED ·Phase: PHASE3
-
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
NCT02020070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
NCT00215657 ·Status: TERMINATED ·Phase: PHASE2
-
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
NCT00884273 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
NCT02468284 ·Status: COMPLETED ·Phase: PHASE1
-
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
NCT00117286 ·Status: COMPLETED ·Phase: PHASE2/PHASE3